A 20-gene model for molecular nodal staging of bladder cancer: Development and prospective assessment

The Lancet Oncology

Volumn 12, Issue 2, 2011, Pages 137-143

  Smith, Steven Christopher ^a   Baras, Alexander Spyridon ^b   Dancik, Garrett ^a   Ru, Yuanbin ^a   Ding, Kuan Fu ^c   Moskaluk, Christopher A ^b   Fradet, Yves ^d   Lehmann, Jan ^e   Stöckle, Michael ^f   Hartmann, Arndt ^g   Lee, Jae K ^c   Theodorescu, Dan ^a,h  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e Urology Practice Prüner Gang   (Germany)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; FEMALE; GENE EXPRESSION MODEL; GENE EXPRESSION PROFILING; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; LYMPH VESSEL; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; SEX RATIO;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; NEOADJUVANT THERAPY; NEOPLASM STAGING; PATIENT CARE PLANNING; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 79151474407     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70296-5     Document Type: Article

References (30)

1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003, 21:1315-1330.
2. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993, 329:1377-1382.
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
5. Hall RR Updated results of a randomized trial of neoadjuvant cisplatin (C) methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 2002, 21:178a. (abstr 710).
6. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005, 2. Advanced Bladder Cancer Meta-analysis Collaboration, CD005246.
7. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007, 178:451-454.
8. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol 2009, 27:5680-5684.
9. Bochner BH, Kattan MW, Vora KC Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006, 24:3967-3972.
10. Lehmann J, Retz M, Wiemers C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005, 23:4963-4974.
11. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789.
12. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15.
13. Bosman FT, Yan P, Tejpar S, et al. Tissue biomarker development in a multicentre trial context: a feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res 2009, 15:5528-5533.
14. Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010, 9:3.
15. Hewitt SM, Lewis FA, Cao Y, et al. Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med 2008, 132:1929-1935.
16. Toussaint J, Sieuwerts AM, Haibe-Kains B, et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 2009, 10:424.
17. van Laar RK, Ma XJ, de Jong D, et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer 2009, 125:1390-1397.
18. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
19. Cheng L, Neumann RM, Weaver AL, et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am J Clin Pathol 2000, 113:275-279.
20. Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol 2008, 180:1928-1932.
21. Shariat SF, Lotan Y, Vickers A, et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010, 28:389-400.
22. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008, 148:358-369.
23. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010, 70:3463-3472.
24. Als AB, Dyrskjot L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007, 13:4407-4414.
25. Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 2005, 11:3773-3777.
26. Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009, 27:4314-4320.
27. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009, 55:761-769.
28. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007, 104:13086-13091.
29. Smith SC, Baras AS, Lee JK, Theodorescu D The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 2010, 70:1753-1758.
30. Williams PD, Cheon S, Havaleshko DM, et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 2009, 69:8302-8309.